Exelixis Inc (EXEL)
23.19
+0.32
(+1.40%)
USD |
NASDAQ |
Apr 23, 10:23
Exelixis Cash from Investing (Quarterly): 61.74M for Dec. 31, 2023
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 61.74M |
| September 30, 2023 | 34.68M |
| June 30, 2023 | -73.78M |
| March 31, 2023 | -49.59M |
| December 31, 2022 | -245.78M |
| September 30, 2022 | -68.95M |
| June 30, 2022 | -135.14M |
| March 31, 2022 | -74.54M |
| December 31, 2021 | -13.06M |
| September 30, 2021 | -21.24M |
| June 30, 2021 | -70.84M |
| March 31, 2021 | 62.26M |
| December 31, 2020 | -29.51M |
| September 30, 2020 | -207.60M |
| June 30, 2020 | 73.27M |
| March 31, 2020 | 32.62M |
| December 31, 2019 | -130.20M |
| September 30, 2019 | -206.46M |
| June 30, 2019 | -142.93M |
| March 31, 2019 | -107.66M |
| December 31, 2018 | -142.80M |
| September 30, 2018 | -63.25M |
| June 30, 2018 | -66.27M |
| March 31, 2018 | -25.53M |
| December 31, 2017 | -18.33M |
| Date | Value |
|---|---|
| September 30, 2017 | -26.59M |
| June 30, 2017 | 47.22M |
| March 31, 2017 | 34.50M |
| December 31, 2016 | -58.91M |
| September 30, 2016 | -12.13M |
| June 30, 2016 | -123.82M |
| March 31, 2016 | -19.68M |
| December 31, 2015 | 24.01M |
| September 30, 2015 | -31.51M |
| June 30, 2015 | 7.685M |
| March 31, 2015 | 49.90M |
| December 31, 2014 | 30.18M |
| September 30, 2014 | 11.10M |
| June 30, 2014 | 44.69M |
| March 31, 2014 | 60.36M |
| December 31, 2013 | 59.50M |
| September 30, 2013 | 18.03M |
| June 30, 2013 | 0.467M |
| March 31, 2013 | 66.35M |
| December 31, 2012 | -99.63M |
| September 30, 2012 | -141.21M |
| June 30, 2012 | 33.64M |
| March 31, 2012 | -52.28M |
| December 31, 2011 | 37.38M |
| September 30, 2011 | 32.56M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-245.78M
Minimum
Dec 2022
73.27M
Maximum
Jun 2020
-63.42M
Average
-68.95M
Median
Sep 2022
Cash from Investing (Quarterly) Benchmarks
| Regeneron Pharmaceuticals Inc | -66.20M |
| Bristol-Myers Squibb Co | -1.346B |
| Johnson & Johnson | -1.202B |
| Bio-Techne Corp | -23.67M |
| Legend Biotech Corp | 407.51M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 10.57M |
| Cash from Financing (Quarterly) | -206.17M |
| Free Cash Flow | 170.36M |
| Free Cash Flow Per Share (Quarterly) | -0.0082 |
| Free Cash Flow to Equity (Quarterly) | -2.564M |
| Free Cash Flow to Firm (Quarterly) | -2.564M |
| Free Cash Flow Yield | 2.29% |